Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05479721 · ClinicalTrials.gov registry record
LITMUS Imaging Study
A clinical trial of NASH - Nonalcoholic Steatohepatitis and NAFLD, sponsored by University of Oxford.
- Active
- Registry status
- 450
- Enrollment target
- 18
- Study locations
NCT05479721: Active study of NASH - Nonalcoholic Steatohepatitis and NAFLD, sponsored by University of Oxford.
NCT05479721 is a study of NASH - Nonalcoholic Steatohepatitis and NAFLD that is active but no longer recruiting, run by University of Oxford. The registered enrollment target is 450 participants, above the 246-participant average among 28 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (83% higher). The trial reports 18 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05479721, a study of NASH - Nonalcoholic Steatohepatitis and NAFLD, is active but no longer recruiting, sponsored by University of Oxford.
- ACTIVE NOT RECRUITING
- Registry status
- 450 participants
- Enrollment target
- 18
- Study locations
Study Summary
The LITMUS Imaging Study is a prospectively recruited, observational study of patients with histologically characterised non-alcoholic fatty liver disease (NAFLD). It aims to evaluate the diagnostic performance of imaging biomarkers (ultrasound elastography and magnetic resonance biomarkers) against NAFLD histological scores in a cross-sectional analysis and the natural history of NAFLD in a longitudinal study.
Primary Outcome
sensitivity, specificity, positive predictive value, negative predictive value, area under the receiver operating characteristic curve
Conditions Studied
Study Locations (18)
Other
- Helsinki University Hospital - Helsinki
- Le Centre de Recherche Clinique (CRC) du CHU d'Angers - Angers
- Institut ICAN - Institute of Cardiometabolism And Nutrition Hôpital de la Pitié Salpêtrière - Paris
- UNIVERSITÄTSMEDIZIN der Johannes Gutenberg Universität Mainz - Mainz
- Universitätsklinikums Würzburg - Würzburg
- Laiko General Hospital of Athens - Athens
- Università di Palermo - Palermo
- Department of Medical Sciences University of Torino - Torino
- Vall d'Hebron University Hospital - Barcelona
- Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocío University Hospital - Seville
- HU Clínico de Valladolid - Valladolid
- Linköping University Hospital - Linköping
- Inselspital, University Hospital - Bern
- Addenbrookes Hospital - Cambridge
- The Newcastle Upon Tyne Hospitals Nhs Foundation Trust - Newcastle upon Tyne
- Queens Medical Centre - Nottingham
- Oxford University Hospitals NHS Foundation Trust - Oxford
Texas
- Pinnacle Clinical Research - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2019-09-04 |
| Est. Completion | 2025-10-31 |
What the registry record for NCT05479721 still lists
NCT05479721 is an observational study that tracks outcomes without assigning an intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, above the 246-participant average among 28 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (83% higher).
The record links to 5 conditions, with NASH - Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 0 interventions.
NCT05479721 lists 18 locations in 2 states (Other, Texas).
Frequently Asked Questions
What is clinical trial NCT05479721 about?
NCT05479721 is a clinical study titled "LITMUS Imaging Study". The LITMUS Imaging Study is a prospectively recruited, observational study of patients with histologically characterised non-alcoholic fatty liver disease (NAFLD). It aims to evaluate the diagnostic performance of imaging biomarkers (ultrasound elastography and magnetic resonance biomarkers) against...
What is the current status of trial NCT05479721?
This trial is currently active not recruiting. The enrollment target is 450 participants. The study started on 2019-09-04. Estimated completion is 2025-10-31.
What conditions does trial NCT05479721 study?
This clinical trial studies the following conditions: NASH - Nonalcoholic Steatohepatitis, NAFLD, NASH, Fibrosis, Liver, Steatosis of Liver.
Who is sponsoring clinical trial NCT05479721?
This trial is sponsored by University of Oxford, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05479721 being conducted?
This trial has 18 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NASH - Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05479721's enrollment target sits among peer trials
450 4th of 28 higher than 25 of 28 other NASH - Nonalcoholic Steatohepatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NASH - Nonalcoholic Steatohepatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
RECRUITING
-
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
RECRUITING · NA
-
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis
RECRUITING · NA
-
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
RECRUITING · Phase 3
-
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
RECRUITING · Phase 3
-
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI